Introduction
First reported in Wuhan, China, on 31 December 2019, an ongoing outbreak of a viral pneumonia in humans has raised acute and grave global concern. The causative pathogen was rapidly identified as a novel β -coronavirus, which has since been formally named as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses. According to the daily report of the National Health Commission of China, the epidemic of SARS-CoV-2 has so far caused 57,416 confirmed cases, including 11,272 severe cases, and 1,665 deaths in China by February 15th, 2020 [1] . The disease caused by SARS-CoV-2 has been recently named as the Coronavirus Disease-2019 by the World Health Organization. Previous studies about the epidemiological and clinical characteristics of COVID-19 showed patients with COVID-19 may develop either mild or severe symptoms of acute respiratory infection, while the mild patients show symptoms of fever, dry cough, fatigue, abnormal chest CT findings but with a good prognosis [2, 3] . In contrast, some patients develop severe pneumonia, acute respiratory distress syndrome (ARDS) or multiple organ failure, with death rates ranging from between 4.3% to 15% according to different study reports [2, 4] .
Lymphopenia and inflammatory cytokine storm are typical laboratory abnormalities observed during highly pathogenic coronavirus infections, such as the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) infections, and are believed to be associated with disease severities [5, 6] . Recent studies have also reported decreases in the counts of lymphocytes in the peripheral blood and increases in serum inflammatory cytokine levels in COVID-19 patients [4, 7] . However, it has remained largely unclear how different lymphocyte subsets and the kinetics of inflammatory cytokines change in the peripheral blood during COVID-19. In this study, we longitudinally characterized the changes of lymphocyte subsets and cytokines profiles in the peripheral blood of COVID-19 patients with distinct disease severities.
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Statistical analyses
Classification variables are expressed in frequency or percentage, and significance is detected by chi square or Fisher's exact test. The quantized variables of parameters are expressed as mean ± standard deviation, and the significance is tested by t-test.
Nonparametric variables were expressed in median and quartile intervals, and significance was tested by Mann Whitney U or Kruskal Wallis test. Data (nonnormal distribution) from repeated measures were compared using the generalized linear 
Results

Demographic and clinical characteristics of COVID-19 patients
The diagnosis of COVID-19 for patients was performed according to the Guidelines Table 1 ). All severe patients and 85.2% of the mild patients had fever, while no significant difference in the degrees of temperature was observed between the two groups ( Table 1 ). The severe patients showed significantly higher frequencies in the occurrence of sputum production (p=0.032), myalgia (p=0.041) and nausea (p=0.029) ( Table 1 ). The levels of fibrinogen (p<0.001), D-dimer (P=0.008), total bilirubin (p=0.007), aspartate transaminase (p<0.001), alanine transaminase (p=0.004), lactate dehydrogenase (p<0.001), creatine kinase (p=0.010), C-reactive protein (p=0.006), ferritin (p=0.015) and serum amyloid A protein (SAA, p=0.003) in the peripheral blood of the severe patients were significantly higher at admission compared to the mild patients (Table 2) . No significant differences in the serum levels of immunoglobulins (IgA, IgG and IgM), complement C3 or C4 were observed between the two groups ( Table 2 ).
Kinetic analysis of lymphocyte subsets in the peripheral blood of COVID-19 patients
Lymphopenia was observed in 44.4% (12/27) of mild patients and 84.6% (11/13) of severe patients at the onset of the disease. As shown in Table 2 , the absolute counts of lymphocytes in the peripheral blood of the severe patients was significantly lower, while the absolute counts of total white blood cells (WBCs) and neutrophils were significantly higher, than those of the mild patients at the time of hospital admission.
No significant difference in monocyte counts was observed between the two groups (Table 2 ). Next, we analyzed the kinetic changes of WBCs, neutrophils and monocytes as well as different lymphocyte subsets in the peripheral blood of COVID-19 patients from the disease onset to at least 16 days later. The two mortalities in the severe group were excluded from the analysis due to the lack of kinetic data. Significant increases in total WBCs counts in the severe group were only observed at the time point of onset (within 3 days) but not during the following period of disease progression compared to the mild group ( Figure 1A ). Significant increases in neutrophil counts of the severe group were observed not only at the time point of disease onset, but also at 13-15 days after compared to the mild group ( Figure 1B) . In contrast, a sustained decrease in lymphocyte counts of the severe group was observed compared to those of the mild patients. The difference was significant at the time point of disease onset and became even greater on 4-6 days later ( Figure 1C ). From 7-15 days after disease onset, the lymphocyte counts gradually increased in the severe group, and reached a comparable level to that of the mild patients at 16 days after disease onset ( Figure 1C ). No significant differences in monocyte counts were observed between the two groups during the whole observation period ( Figure 1D ).
In order to further determine the kinetic changes of different lymphocyte subsets in the peripheral blood of COVID-19 patients, we performed flow cytometry to stain CD3 + T cells, CD4 + and CD8 + T cell subsets, B cells and NK cells. Similar to the findings for lymphocytes, sustained decreases in CD3, CD8 and CD4 T cell counts was observed in the severe group compared to those of the mild patients during clinical observation (Figure 2A-C, Supplementary figure 1 ). The lowest CD3, CD4 and CD8 T cell counts were observed at 4-6 days after disease onset (Figure 2A -C).
The differences in CD3 and CD8 T cell counts between the two groups were significant at the time points of disease onset and 7-9 days later (Figure 2A and 2C) .
However, the differences in CD4 T cell counts between the two groups did not reach a statistical significance at any time point ( Figure 2C ). The T cell counts started to gradually increase in the severe group starting at 7 days after disease onset, and reached comparable levels to those in the mild patients on day 16 after disease onset ( 
Kinetic analysis of inflammatory cytokine levels in the serum of COVID-19 patients
A previous study demonstrated changes in inflammatory cytokine levels, such as IL-2, IL-7, IL-10, and TNF-α, in the serum of COVID-19 patients [2] . Therefore, we further characterized the kinetic changes of inflammatory cytokine levels, including IL-2, IL-4, IL-6, IL-10, IFN-γ and TNF-α, in the serum of our patient cohort. Fluctuations in the serum levels of these cytokines in the mild patient group were minor. In contrast, the severe patient group showed more significant fluctuations in the serum levels of these cytokines (Figure 3 ). All examined cytokines, except IL-6, reached their peak levels in the serum at 3-6 days after disease onset ( Figure 3 ). Both IL-6 and IL-10 levels showed sustained increases in the severe group compared to the mild group ( Figure 3A and 3B). A decease in serum IL-6 levels in the severe group started at 16 days after disease onset, and IL-10 levels were lowest at 13 days after disease onset ( Figure 3A and 3B). Significant increases in serum IL-2 and IFN-γ levels in the severe group were only observed at 4-6 days after disease onset ( Figure 3C and 3F).
No significant differences in IL4 and TNF-α levels were observed between the two groups during the whole course of the disease ( Figure 3D and 3E). All examined cytokines reached similar levels between the severe and mild patient groups at 16 days after disease onset (Figure 3 ).
Prognostic factors for identification of severe COVID-19 cases
Next, we examined the possibilities of using above-mentioned parameters as prognostic factors for identifying severe cases in COVID-19 patients. PCA was firstly performed by R package "factoextra" to identify correlated variables for distinguishing severe patients from mild patients ( Figure 4A) 
Discussion
In this study, we analyzed the clinical features and immunological characteristics of peripheral blood in patients with COVID-19. Although the majority of the patients did not have an exposure history of the Huanan seafood market in Wuhan, the clinical characteristics of these patients are very similar to those reported in previous studies [2, 4, 7] . The ages of severe patients are older, and the proportion of underlying diseases is higher, and co-infection also occurs in severe patients. Recent reports show that the lymphocyte counts are normal in COVID-19 patients with mild diseases. In contrast, 63%-70.3% of patients with severe diseases have lymphopenia and the lymphocyte counts in patients with a mortal outcome remain at a low level [4, 8] . Our study also confirmed higher rates of developing lymphopenia in severe patients than in mild patients (84.6% vs 44.4%). We found that the development of lymphopenia in severe patients was mainly related to the significantly decreased absolute counts of T
cells, especially CD8 + T cells, but not to B cells and NK cells. The decrease of T cells
in the severe patient group reaches its peak within the first week during the disease course, and then T cell numbers gradually increase from the second week and recover to a comparable level to that of the mild patient group in the third week. All these severe patients included in our study survived the disease, and thus we speculate this course is associated with a favorable outcome in severe COVID-19 patients.
Previous researches on SARS-CoV and MERS-CoV infections have demonstrated the correlation between T cell counts and the severity of the diseases, as well as explored
the possible mechanisms [9] . It has been shown that the acute SARS-CoV infection was associated with marked lymphopenia in about 80% of patients, including a dramatic loss of both CD4 + and CD8 + T cells in comparison with healthy control individuals [10] [11] [12] . Decreases in T cell numbers are strongly correlated with the severity of acute phase of SARS disease in patients [11, 13] . Lymphopenia is also observed in MERS-CoV infected patients. A detailed clinical study showed that 14 % of MERS patients had leukopenia, while 34 % of the patients had lymphopenia [14] .
The mechanism of developing lymphopenia may differ in SARS-CoV and
MERS-CoV infections. SARS-CoV cannot productively infect T cells, however, altered antigen presenting cells (APC) function and impaired dendritic cells migration during SARS-CoV infection may result in insufficient T cell priming and thus
contribute to decreased numbers of virus-specific T cells in the lungs [15, 16] .
Moreover, delayed type I interferon response or inflammatory monocyte-macrophages derived pro-inflammatory cytokines could also sensitize T cells to undergo apoptosis [17] . In contrast, MERS-CoV was found to be able to infect many human immune cells, including dendritic cells[18], macrophages [19] , and T cells[20]. A recent study in a 61-patient cohort reported that the NLR was the most useful prognostic factor affecting the prognosis for severe COVID-19 [24] . The severity of pathological injury during SARS or MERS correlates with the extensive infiltration of neutrophils in the lung and increased neutrophil numbers in the peripheral blood [17] .
MERS-CoV infection of T cells results in apoptosis mediated
Thus, the magnitude of increase in neutrophil counts may suggest the intensity of inflammatory responses in COVID-19 patients. Besides, the magnitude of decrease in lymphocyte counts also indicates the extend of the impairment of immune system by the viral infection. Therefore, NLR may serve as a useful factor to reflect the intensity of imbalance of inflammation and immune responses in COVID-19 patients. In this study, we also screened the potential prognostic factors affecting incidence of severe illness in our patient cohort. Based on our findings with analyzing lymphocyte subsets, we further included the ratio of neutrophils to different lymphocyte subsets as parameters. Our kinetic analysis revealed that CD8 + T cells are the major lymphocyte subset which decreases in cell numbers during COVID-19. In line with this finding, our results demonstrate that N8R has even better performance with a higher AUC value than NLR in the ROC curve analysis, and may serve as a more powerful factor than NLR for predicting the severe illness incidence in COVID patients.
In summary, our study of immunological characteristics of the peripheral blood in COVID-19 patients shows that the numbers of neutrophils and T cells, especially CD8 + T cells, as well as the levels of inflammatory cytokines in the peripheral blood is dynamically correlated with the severity of the disease. To the best of our knowledge, this is the first work to describe the kinetic changes of lymphocyte subsets and cytokine profiles in COVID-19 patients. Importantly, we identified N8R and NLR as powerful prognostic factors for early identification of severe COVID-19 cases.
This work may help to achieve a better understanding of immune function disorder as well as immunopathogenesis during SARS-CoV-2 infection.
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